SavedAdd your journal

Journals / Eurasian Journal of Medical Investigation / 2021 / Cilt: 5 - Sayı: 1

Chemotherapy Agents Used in the COVID-19 Pandemic and Previous Years in Non-Small Cell Lung Cancer Patients and Their Effects on Periodic Mortality: A Single-Center Experience

Ayşe DEMİRCİ
İlhan HACIBEKİROĞLU
Pages
142–147
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Palliative anticancer therapy rates were 85.2% in the first group, 87.7% in the second group, and 74.4% in the PPG(p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: The objective of the study was to evaluate chemotherapy agents used in the coronavirus disease-19 (COVID-19) pandemic and previous years and compare mortality rates of non-small cell lung cancer (NSCLC) patients whowere receiving anticancer therapy.Methods: Patients were analyzed retrospectively in three different groups; the first group (December 1, 2017-May 31,2018), the second group (December 1, 2018-May 31, 2019), and the pandemic period group (PPG) (December 1, 2019-May 31, 2020).Results: A total of 608 NSCLC patients were evaluated, 183 in the first group, 206 in the second group, and 219 in thePPG.
📊
Key Findings & Data:Objectives: The objective of the study was to evaluate chemotherapy agents used in the coronavirus disease-19 (COVID-19) pandemic and previous years and compare mortality rates of non-small cell lung cancer (NSCLC) patients whowere receiving anticancer therapy.Methods: Patients were analyzed retrospectively in three different groups; the first group (December 1, 2017-May 31,2018), the second group (December 1, 2018-May 31, 2019), and the pandemic period group (PPG) (December 1, 2019-May 31, 2020).Results: A total of 608 NSCLC patients were evaluated, 183 in the first group, 206 in the second group, and 219 in thePPG.
💡
Conclusion & Impact:Palliative anticancer therapy rates were 85.2% in the first group, 87.7% in the second group, and 74.4% in the PPG(p
🔬Design:Research Article
📍Scope:2017 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: The objective of the study was to evaluate chemotherapy agents used in the coronavirus disease-19 (COVID-19) pandemic and previous years and compare mortality rates of non-small cell lung cancer (NSCLC) patients whowere receiving anticancer therapy.Methods: Patients were analyzed retrospectively in three different groups; the first group (December 1, 2017-May 31,2018), the second group (December 1, 2018-May 31, 2019), and the pandemic period group (PPG) (December 1, 2019-May 31, 2020).Results: A total of 608 NSCLC patients were evaluated, 183 in the first group, 206 in the second group, and 219 in thePPG. Palliative anticancer therapy rates were 85.2% in the first group, 87.7% in the second group, and 74.4% in the PPG(p

🔖

Cite This Article

DEMİRCİ, A., HACIBEKİROĞLU, İ. (2022). Chemotherapy Agents Used in the COVID-19 Pandemic and Previous Years in Non-Small Cell Lung Cancer Patients and Their Effects on Periodic Mortality: A Single-Center Experience. Eurasian Journal of Medical Investigation, Cilt: 5 - Sayı: 1, 142–147. https://ajindex.com/articles/508593

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Yalçın G, Sayınbatur B, Karay E, Karakaş M. Psychological stress of healthcare workers caused by the COVID-19 pandemic. Dicle Med J 2020;47:525–41
  2. World Health Organization. Coronavirus Disease 2019 (COVID-19) Situation Report-51. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19. pdf?sfvrsn=1ba62e57_10. Accessed Dec 25, 2020
  3. Yu J, Ouyang W, Chua ML, Xie C. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China. JAMA Oncol 2020;6:1108–10
  4. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China. Lancet Oncol 2020;21:335–7
  5. Zhang L, Zhu F, Xie C, Wang C, Wang J, Chen R, et al. Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China. Ann Oncol 2020;31:894–901
  6. Lung Cancer Study Group, Chinese Thoracic Society, Chinese Medical Association, Chinese Respiratory Oncology Collaboration. [Expert recommendations on the management of patients with advanced non-small cell lung cancer during epidemic of coronavirus disease 2019 (Trial version)]. Zhonghua Jie He He Hu Xi Za Zhi 2020;43:297–301
  7. Europian Society of Medical Oncology. Cancer Patient Management During COVID-19 Pandemic. Lung Cancer in the COVID-19 Area. Available at: https://www.esmo.org/guidelines/ cancer-patient-management-during-the-covid-19-pandemic/lung-cancer-in-the-covid-19-era. Accessed Dec 25, 2020
  8. Yang K, Sheng Y, Huang C, Jin Y, Xiong N, Jiang K, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: A multicentre, retrospective, cohort study. Lancet Oncol 2020;21:904–13
  9. National Comprehensive Cancer Network. Hematopoietic Growth Factors, Version 2; 2020. Available at: https://www. nccn.org/professionals/physician_gls/pdf/growthfactors.pdf. Accessed Dec 25, 2020
  10. Luo J, Rizvi H, Preeshagul I, Egger JV, Hoyos D, Bandlamudi C, et al. COVID-19 in patients with lung cancer. Ann Oncol 2020;31:1386–96
  11. Rogado J, Pangua C, Serrano-Montero G, Obispo B, Marino AM, Pérez-Pérez M, et al. COVID-19 and lung cancer: A greater fatality rate? Lung Cancer 2020;146:19–22
  12. Rogado J, Obispo B, Pangua C, Serrano-Montero G, Marino AM, Pérez-Pérez M, et al. COVID-19 transmission, outcome and associated risk factors in cancer patients at the first month of the pandemic